Instead of relying primarily on historical relationships, many sponsors are exploring more data-driven approaches to site selection, including: regional disease heatmaps investigator performance analytics patient population modeling AI-assisted feasibility analysis These approaches aim to answer a fundamental question: Which sites can actually recruit the patients required for modern metabolic trials
It usually depends on several factors such as baseline metabolism, lifestyle habits, and treatment duration
Anti-inflammatory mechanism at low doses The anti-inflammatory effects of GLP-1R agonism are not dose-dependent in the same way that weight loss is
GLP-1 medications such as Ozempic, Wegovy, and Mounjaro have transformed obesity treatment by enabling significant, sustained weight loss
This is both a legal obligation and a patient care touchpoint
Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA